Cathaline den Besten is a seasoned nonclinical expert with over 30 years of experience in translational drug development, toxicology and DMPK. She has gained wide-ranging R&D experience from early research to late-stage clinical development and marketed product support across multiple drug platforms. Since 2011 she has been dedicated to progressing novel RNA therapies to patients with rare diseases. In her role as Vice President Nonclinical Development at ProQR Therapeutics, Cathaline was responsible for the nonclinical and translational data packages for sepofarsen and ultevursen. She has authored multiple papers and book chapters on the PK and safety of antisense oligonucleotides.